PDCD1 and neoplasm: Additionally, we predicted that MHC-I would bind to tumor neo-antigens in patients receiving PD-1 blockade therapy (Supplementary Methods), while patients who responded to immunotherapy did not show high abundance of cancer neo-antigens (Supplementary Figure S3C and Supplementary Table 3).